AstraZeneca deal failed due to price, says Pfizer CFO
This article was originally published in Scrip
Pfizer's CFO Frank D'Amelio says the AstraZeneca transaction failed to go ahead because of just one reason: price. "Any other items or issues that were raised during the negotiations, we were able to adequately and effectively address. When all was said and done, the reason the deal didn't get done was because of price."
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.